Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Anti-cancer antibody-drug conjugates (ADCs) aim to expand the therapeutic index of traditional chemotherapy by employing the targeting specificity of monoclonal antibodies (mAbs) to increase the efficiency of the delivery of potent cytotoxic agents to malignant cells. In the past three years, the number of ADCs approved by the Food and Drug Administration (FDA) has tripled. Although several ADCs have demonstrated sufficient efficacy and safety to warrant FDA approval, the clinical use of all ADCs leads to substantial toxicity in treated patients, and many ADCs have failed during clinical development due to their unacceptable toxicity profiles. Analysis of the clinical data has demonstrated that dose-limiting toxicities (DLTs) are often shared by different ADCs that deliver the same cytotoxic payload, independent of the antigen that is targeted and/or the type of cancer that is treated. DLTs are commonly associated with cells and tissues that do not express the targeted antigen (i.e., off-target toxicity), and often limit ADC dosage to levels below those required for optimal anti-cancer effects. In this manuscript, we review the fundamental mechanisms contributing to ADC toxicity, we summarize common ADC treatment-related adverse events, and we discuss several approaches to mitigating ADC toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bispecific ADCs have increased selectivity and internalization, as well as may limit ADC binding to normal tissue, reducing on-target off-tumor toxicity5,230.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [230]
Experimental — accuracy not yet measuredIn the citing paper
“their substantial toxicity (primarily affecting the bone marrow) must be considered.69 70”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151 · cited 1×
“The intent is to enhance tumor selectivity through preferential activation within the tumor microenvironment, where upregulated protease activity [208,209] cleaves the masking peptide, thus enabling PDC binding to the target antigen.”
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 1×
“6 mg/kg every three weeks) or with lapatinib plus capecitabine [124].”
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006 · cited 2×
“The pivotal single-arm phase 2 DESTINY-Breast01 clinical trial consisted of two parts [65].”
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Neutrophil kinetics in health and disease
Summers, C., Rankin, S. M., Condliffe, A. M., Singh, N., Peters, A. M., & Chilvers, E. R. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.05.006 · Cited by 1,242
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Self-citationAntibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Self-citationAntibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812 · cited 1×
“4 mg/kg (99 patients) once every three weeks [118].”
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, L. H., Herrera, A. F., Flowers, C. R., Kamdar, M. K., McMillan, A., Hertzberg, M., Assouline, S., Kim, T. M., Kim, W. S., Ozcan, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00172 · Cited by 774
Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60165-9 · Cited by 742
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
Cleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro-Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 652
Rosenberg, J. E., O’Donnell, P. H., Balar, A. V., McGregor, B. A., Heath, E. I., Yu, E. Y., Galsky, M. D., Hahn, N. M., Gartner, E. M., Pinelli, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01140 · Cited by 642
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Agarwal, P., & Bertozzi, C. R. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5004982 · Cited by 605
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., Jonas, M., Anderson, M. E., Setter, J. R., & Senter, P. D. (2015) · Nature Biotechnology · doi:10.1038/nbt.3212 · Cited by 557
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Donaghy, H. (2016) · mAbs · doi:10.1080/19420862.2016.1156829 · Cited by 495
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Grisold, W., Cavaletti, G., & Windebank, A. J. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos203 · Cited by 486
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V., & Flynn, G. C. (2011) · Glycobiology · doi:10.1093/glycob/cwr027 · Cited by 467 · cited 1×
“For example, the systemic clearance of therapeutic IgGs with a high level of mannosylation is significantly faster than that of normal IgGs in humans [56].”
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Larson, R. A., Sievers, E. L., Stadtmauer, E. A., Löwenberg, B., Estey, E. H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J. M., Richie, M., et al. (2005) · Cancer · doi:10.1002/cncr.21326 · Cited by 460
Caimi, P. F., Ai, W., Alderuccio, J. P., Ardeshna, K. M., Hamadani, M., Hess, B., Kahl, B. S., Radford, J., Solh, M., Stathis, A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00139-x · Cited by 441
van Rhenen, A., van Dongen, G. A. M. S., Kelder, A., Rombouts, E. J., Feller, N., Moshaver, B., Walsum, M. S.-V., Zweegman, S., Ossenkoppele, G. J., & Jan Schuurhuis, G. (2007) · Blood · doi:10.1182/blood-2007-03-083048 · Cited by 439
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00056-5 · Cited by 410
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F.-P., Fielder, P. J., & Khawli, L. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100261d · Cited by 398
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
McCombs, J. R., & Owen, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9710-8 · Cited by 393
Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Reversal of Advanced Digoxin Intoxication with Fab Fragments of Digoxin-Specific Antibodies
Smith, T. W., Haber, E., Yeatman, L., & Butler, V. P. (1976) · New England Journal of Medicine · doi:10.1056/nejm197604082941501 · Cited by 377
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372 · cited 2×
“1% of the inject d dose of an ADC is delivered to the t rgeted diseased cell populatio , wi h the vast majority of the administered ose catabolized “off-site” within non-targeted healthy cells, potentially leading to unwanted toxicities [16,17].”
Amadori, S., Suciu, S., Selleslag, D., Aversa, F., Gaidano, G., Musso, M., Annino, L., Venditti, A., Voso, M. T., Mazzone, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0060 · Cited by 362
Lambert, J., Pautas, C., Terré, C., Raffoux, E., Turlure, P., Caillot, D., Legrand, O., Thomas, X., Gardin, C., Gogat-Marchant, K., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.188888 · Cited by 361
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
A novel connector linkage applicable in prodrug design
Carl, P. L., Chakravarty, P. K., & Katzenellenbogen, J. A. (1981) · Journal of Medicinal Chemistry · doi:10.1021/jm00137a001 · Cited by 351
Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340
Rosenberg, J., Sridhar, S. S., Zhang, J., Smith, D., Ruether, D., Flaig, T. W., Baranda, J., Lang, J., Plimack, E. R., Sangha, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02044 · Cited by 338
Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., Patel, M. R., Sangha, R., Hagenbeek, A., Advani, R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70128-2 · Cited by 336
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0180-3 · Cited by 336
Moore, K. N., Oza, A. M., Colombo, N., Oaknin, A., Scambia, G., Lorusso, D., Konecny, G. E., Banerjee, S., Murphy, C. G., Tanyi, J. L., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.017 · Cited by 305
Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
Masters, J. C., Nickens, D. J., Xuan, D., Shazer, R. L., & Amantea, M. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0520-6 · Cited by 296
Lahoz-Beneytez, J., Elemans, M., Zhang, Y., Ahmed, R., Salam, A., Block, M., Niederalt, C., Asquith, B., & Macallan, D. (2016) · Blood · doi:10.1182/blood-2016-03-700336 · Cited by 293
Sacituzumab Govitecan: First Approval
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01337-5 · Cited by 293
Coats, S., Williams, M., Kebble, B., Dixit, R., Tseng, L., Yao, N.-S., Tice, D. A., & Soria, J.-C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0272 · Cited by 289
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
Linkers Having a Crucial Role in Antibody–Drug Conjugates
Lu, J., Jiang, F., Lu, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040561 · Cited by 285
Sun, X., Ponte, J. F., Yoder, N. C., Laleau, R., Coccia, J., Lanieri, L., Qiu, Q., Wu, R., Hong, E., Bogalhas, M., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00062 · Cited by 277
Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
Eaton, J. S., Miller, P. E., Mannis, M. J., & Murphy, C. J. (2015) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2015.0064 · Cited by 276
Stepan, L. P., Trueblood, E. S., Hale, K., Babcook, J., Borges, L., & Sutherland, C. L. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411410430 · Cited by 271
Norsworthy, K. J., Ko, C.-W., Lee, J. E., Liu, J., John, C. S., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0604 · Cited by 269
New developments for antibody-drug conjugate-based therapeutic approaches
de Goeij, B. E., & Lambert, J. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.008 · Cited by 256
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Trudel, S., Lendvai, N., Popat, R., Voorhees, P. M., Reeves, B., Libby, E. N., Richardson, P. G., Anderson, L. D., Sutherland, H. J., Yong, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30576-x · Cited by 250
Morschhauser, F., Flinn, I. W., Advani, R., Sehn, L. H., Diefenbach, C., Kolibaba, K., Press, O. W., Salles, G., Tilly, H., Chen, A. I., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30026-2 · Cited by 249
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy
Rajvanshi, P., Shulman, H. M., Sievers, E. L., & McDonald, G. B. (2002) · Blood · doi:10.1182/blood.v99.7.2310 · Cited by 246
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Ab, O., Whiteman, K. R., Bartle, L. M., Sun, X., Singh, R., Tavares, D., LaBelle, A., Payne, G., Lutz, R. J., Pinkas, J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1095 · Cited by 237
Antibody-Drug Conjugates: Possibilities and Challenges.
Nejadmoghaddam, M.-R., Minai‐Tehrani, A., Ghahremanzadeh, R., Mahmoudi, M., Dinarvand, R., & Zarnani, A. (2019) · PubMed Central · Cited by 237
de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30859-3 · Cited by 237
Conte, P., Ascierto, P. A., Patelli, G., Danesi, R., Vanzulli, A., Sandomenico, F., Tarsia, P., Cattelan, A., Comes, A., De Laurentiis, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100404 · Cited by 235
Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Flowers, D. A., & Bernstein, I. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0100206 · Cited by 230
Williams, R. J., Tse, T., DiPiazza, K., & Zarin, D. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127242 · Cited by 226
Anami, Y., Yamazaki, C. M., Xiong, W., Gui, X., Zhang, N., An, Z., & Tsuchikama, K. (2018) · Nature Communications · doi:10.1038/s41467-018-04982-3 · Cited by 226
Elgersma, R. C., Coumans, R. G. E., Huijbregts, T., Menge, W. M. P. B., Joosten, J. A. F., Spijker, H. J., de Groot, F. M. H., van der Lee, M. M. C., Ubink, R., van den Dobbelsteen, D. J., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500781a · Cited by 221
Polatuzumab Vedotin: First Global Approval
Deeks, E. D. (2019) · Drugs · doi:10.1007/s40265-019-01175-0 · Cited by 221
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Uppal, H., Doudement, E., Mahapatra, K., Darbonne, W. C., Bumbaca, D., Shen, B.-Q., Du, X., Saad, O., Bowles, K., Olsen, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2093 · Cited by 218
Kantarjian, H. M., DeAngelo, D. J., Advani, A. S., Stelljes, M., Kebriaei, P., Cassaday, R. D., Merchant, A. A., Fujishima, N., Uchida, T., Calbacho, M., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30103-5 · Cited by 217
Dorywalska, M., Dushin, R., Moine, L., Farias, S. E., Zhou, D., Navaratnam, T., Lui, V., Hasa-Moreno, A., Casas, M. G., Tran, T.-T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1004 · Cited by 216
Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., Widdison, W. C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002958 · Cited by 215
Argu¨eso, P., Spurr-Michaud, S., Russo, C. L., Tisdale, A., & Gipson, I. K. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0862 · Cited by 212
Drake, P. M., Albers, A. E., Baker, J., Banas, S., Barfield, R. M., Bhat, A. S., de Hart, G. W., Garofalo, A. W., Holder, P., Jones, L. C., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500189z · Cited by 212
Pericellular proteolysis in cancer
Sevenich, L., & Joyce, J. A. (2014) · Genes & Development · doi:10.1101/gad.250647.114 · Cited by 193
Zhu, Y., Liu, K., Wang, K., & Zhu, H. (2023) · Cancer · doi:10.1002/cncr.34507 · Cited by 192
Yardley, D. A., Weaver, R., Melisko, M. E., Saleh, M. N., Arena, F. P., Forero, A., Cigler, T., Stopeck, A., Citrin, D., Oliff, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2959 · Cited by 190
Casi, G., & Neri, D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00457 · Cited by 189
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Chang, E., Weinstock, C., Zhang, L., Charlab, R., Dorff, S. E., Gong, Y., Hsu, V., Li, F., Ricks, T. K., Song, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2275 · Cited by 189
Autio, K. A., Boni, V., Humphrey, R. W., & Naing, A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1457 · Cited by 184
ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
Zammarchi, F., Corbett, S., Adams, L., Tyrer, P. C., Kiakos, K., Janghra, N., Marafioti, T., Britten, C. E., Havenith, C. E. G., Chivers, S., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813493 · Cited by 181
Hamadani, M., Radford, J., Carlo-Stella, C., Caimi, P. F., Reid, E., O’Connor, O. A., Feingold, J. M., Ardeshna, K. M., Townsend, W., Solh, M., et al. (2021) · Blood · doi:10.1182/blood.2020007512 · Cited by 178
Ahmadi, M., Bryson, C. J., Cloake, E. A., Welch, K., Filipe, V., Romeijn, S., Hawe, A., Jiskoot, W., Baker, M. P., & Fogg, M. H. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1541-x · Cited by 177
An FDA oncology analysis of antibody-drug conjugates
Saber, H., & Leighton, J. K. (2015) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2015.01.014 · Cited by 177
Evolving Strategies for Target Selection for Antibody-Drug Conjugates
Damelin, M. I., Zhong, W., Myers, J. S., & Sapra, P. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1624-3 · Cited by 172
Methods for site-specific drug conjugation to antibodies
Behrens, C. R., & Liu, B. (2014) · mAbs · doi:10.4161/mabs.26632 · Cited by 171
Kumagai, K., Aida, T., Tsuchiya, Y., Kishino, Y., Kai, K., & Mori, K. (2020) · Cancer Science · doi:10.1111/cas.14686 · Cited by 171
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
Narayan, P., Osgood, C. L., Singh, H., Chiu, H.-J., Ricks, T. K., Chiu Yuen Chow, E., Qiu, J., Song, P., Yu, J., Namuswe, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4557 · Cited by 167
Andreev, J., Thambi, N., Perez Bay, A. E., Delfino, F., Martin, J., Kelly, M. P., Kirshner, J. R., Rafique, A., Kunz, A., Nittoli, T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0658 · Cited by 166
Tiberghien, A. C., Levy, J.-N., Masterson, L. A., Patel, N. V., Adams, L. R., Corbett, S., Williams, D. G., Hartley, J. A., & Howard, P. W. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00062 · Cited by 164
Disitamab Vedotin: First Approval
Deeks, E. D. (2021) · Drugs · doi:10.1007/s40265-021-01614-x · Cited by 164
Lacouture, M. E., Patel, A. B., Rosenberg, J. E., & O’Donnell, P. H. (2022) · The Oncologist · doi:10.1093/oncolo/oyac001 · Cited by 158
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates
Burke, P. J., Hamilton, J. Z., Jeffrey, S. C., Hunter, J. H., Doronina, S. O., Okeley, N. M., Miyamoto, J. B., Anderson, M. E., Stone, I. J., Ulrich, M. L., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0343 · Cited by 155
Improving target cell specificity using a novel monovalent bispecific IgG design
Mazor, Y., Oganesyan, V., Yang, C., Hansen, A., Wang, J., Liu, H., Sachsenmeier, K., Carlson, M., Gadre, D. V., Borrok, M. J., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007816 · Cited by 149
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Shor, B., Gerber, H., & Sapra, P. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.014 · Cited by 149
Kim, M. T., Chen, Y., Marhoul, J., & Jacobson, F. (2014) · Bioconjugate Chemistry · doi:10.1021/bc5000109 · Cited by 146
Mechanisms underlying skin disorders induced by EGFR inhibitors
Holcmann, M., & Sibilia, M. C. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1004969 · Cited by 145
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
Rowe, J. M., & Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2013-03-490482 · Cited by 145
Galsky, M. D., Eisenberger, M., Moore-Cooper, S., Kelly, W. K., Slovin, S. F., DeLaCruz, A., Lee, Y., Webb, I. J., & Scher, H. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0532 · Cited by 145
Current Status: Site-Specific Antibody Drug Conjugates
Schumacher, D., Hackenberger, C. P. R., Leonhardt, H., & Helma, J. (2016) · Journal of Clinical Immunology · doi:10.1007/s10875-016-0265-6 · Cited by 144
Moore, K. N., Borghaei, H., O'Malley, D. M., Jeong, W., Seward, S. M., Bauer, T. M., Perez, R. P., Matulonis, U. A., Running, K. L., Zhang, X., et al. (2017) · Cancer · doi:10.1002/cncr.30736 · Cited by 144
Siegel, P., Rose, Annis, & Maric (2013) · OncoTargets and Therapy · doi:10.2147/ott.s44906 · Cited by 143
Zhao, H., Atkinson, J., Gulesserian, S., Zeng, Z., Nater, J., Ou, J., Yang, P., Morrison, K., Coleman, J., Malik, F., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3202 · Cited by 143
Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates
Pillow, T. H., Sadowsky, J. D., Zhang, D., Yu, S.-F., Del Rosario, G., Xu, K., He, J., Bhakta, S., Ohri, R., Kozak, K. R., et al. (2017) · Chemical Science · doi:10.1039/c6sc01831a · Cited by 142
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
Goldenberg, D. M., & Sharkey, R. M. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1757067 · Cited by 141
Liu, J. F., Moore, K. N., Birrer, M. J., Berlin, S., Matulonis, U. A., Infante, J. R., Wolpin, B. M., Poon, K. A., Firestein, R., Xu, J. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw401 · Cited by 140
Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
de Goeij, B. E. C. G., Vink, T., ten Napel, H., Breij, E. C. W., Satijn, D., Wubbolts, R., Miao, D., & Parren, P. W. H. I. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0364 · Cited by 138
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
Singh, A. P., Sharma, S., & Shah, D. K. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9495-8 · Cited by 138
Tisotumab Vedotin: First Approval
Markham, A. (2021) · Drugs · doi:10.1007/s40265-021-01633-8 · Cited by 136
DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., Vandendries, E., Liau, K., Ananthakrishnan, R., Boni, J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016001925 · Cited by 135
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Hong, D. S., Concin, N., Vergote, I., de Bono, J. S., Slomovitz, B. M., Drew, Y., Arkenau, H.-T., Machiels, J.-P., Spicer, J. F., Jones, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2962 · Cited by 135
Tannir, N. M., Forero, A., Ramchandren, R., Pal, S. K., Ansell, S. M., Infante, J. R., de Vos, S., Hamlin, P. A., Kim, S. K., Whiting, N. C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0151-0 · Cited by 128
Impact of Payload Hydrophobicity on the Stability of Antibody–Drug Conjugates
Buecheler, J. W., Winzer, M., Tonillo, J., Weber, C., & Gieseler, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00177 · Cited by 128
Mazor, Y., Sachsenmeier, K. F., Yang, C., Hansen, A., Filderman, J., Mulgrew, K., Wu, H., & Dall’Acqua, W. F. (2017) · Scientific Reports · doi:10.1038/srep40098 · Cited by 126
Flynn, M. J., Zammarchi, F., Tyrer, P. C., Akarca, A. U., Janghra, N., Britten, C. E., Havenith, C. E. G., Levy, J.-N., Tiberghien, A., Masterson, L. A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0233 · Cited by 124
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Wolska, A., & Robak, T. (2019) · Drug Safety · doi:10.1007/s40264-018-0775-7 · Cited by 124
IgG-effector functions: “The Good, The Bad and The Ugly”
Kapur, R., Einarsdottir, H., & Vidarsson, G. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.01.015 · Cited by 118
Loncastuximab Tesirine: First Approval
Lee, A. (2021) · Drugs · doi:10.1007/s40265-021-01550-w · Cited by 117
Gorovits, B., & Krinos‐Fiorotti, C. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1369-3 · Cited by 116
Trastuzumab Emtansine: First Global Approval
Ballantyne, A. D., & Dhillon, S. (2013) · Drugs · doi:10.1007/s40265-013-0050-2 · Cited by 114
Ohri, R., Bhakta, S., Fourie-O’Donohue, A., dela Cruz-Chuh, J., Tsai, S. P., Cook, R., Wei, B., Ng, C., Wong, A. W., Bos, A. B., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00791 · Cited by 109
Hackshaw, M. D., Danysh, H. E., Singh, J., Ritchey, M. E., Ladner, A., Taitt, C., Camidge, D. R., Iwata, H., & Powell, C. A. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05754-8 · Cited by 104
Beeram, M., Krop, I. E., Burris, H. A., Girish, S. R., Yu, W., Lu, M. W., Holden, S. N., & Modi, S. (2012) · Cancer · doi:10.1002/cncr.27622 · Cited by 103
A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity
Miller, M. L., Fishkin, N. E., Li, W., Whiteman, K. R., Kovtun, Y., Reid, E. E., Archer, K. E., Maloney, E. K., Audette, C. A., Mayo, M. F., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0184 · Cited by 102
Li, F., Sutherland, M. K., Yu, C., Walter, R. B., Westendorf, L., Valliere-Douglass, J., Pan, L., Cronkite, A., Sussman, D., Klussman, K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0742 · Cited by 102
Saura, C., O’Shaughnessy, J., Aftimos, P. G., van den Tweel, E., Oesterholt, M., Escrivá-de-Romaní, S., Tueux, N. Q., Tan, T. Y., Lim, J. S. J., Ladoire, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2088 · Cited by 101
Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends
Drake, P. M., & Rabuka, D. (2017) · BioDrugs · doi:10.1007/s40259-017-0254-1 · Cited by 100
Aoyama, M., Tada, M., Yokoo, H., Demizu, Y., & Ishii‐Watabe, A. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03158-x · Cited by 99
Ott, P. A., Hamid, O., Pavlick, A. C., Kluger, H., Kim, K. B., Boasberg, P. D., Simantov, R., Crowley, E., Green, J. A., Hawthorne, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8115 · Cited by 97
Cheng, X., Li, J., Tanaka, K., Majumder, U., Milinichik, A. Z., Verdi, A. C., Maddage, C. J., Rybinski, K. A., Fernando, S., Fernando, D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1215 · Cited by 95
Ansell, S. M. (2014) · Blood · doi:10.1182/blood-2014-06-537514 · Cited by 93
Sellmann, C., Doerner, A., Knuehl, C., Rasche, N., Sood, V., Krah, S., Rhiel, L., Messemer, A., Wesolowski, J., Schuette, M., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753491 · Cited by 91
A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise
Zhao, H., Gulesserian, S., Malinao, M. C., Ganesan, S. K., Song, J., Chang, M. S., Williams, M. M., Zeng, Z., Mattie, M., Mendelsohn, B. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0133 · Cited by 90
An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
Saber, H., Simpson, N., Ricks, T. K., & Leighton, J. K. (2019) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2019.104429 · Cited by 90
Advances in bispecific biotherapeutics for the treatment of cancer
May, C., Sapra, P., & Gerber, H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.011 · Cited by 87
Insights into the molecular basis of a bispecific antibody's target selectivity
Mazor, Y., Hansen, A., Yang, C., Chowdhury, P. S., Wang, J., Stephens, G., Wu, H., & Dall’Acqua, W. F. (2015) · mAbs · doi:10.1080/19420862.2015.1022695 · Cited by 84
Graf, M., Hecht, K., Reif, S., Pelka‐Fleischer, R., Pfister, K., & Schmetzer, H. M. (2004) · European Journal Of Haematology · doi:10.1046/j.0902-4441.2003.00184.x · Cited by 82
Simmons, J. K., Burke, P. J., Cochran, J. H., Pittman, P. G., & Lyon, R. P. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114932 · Cited by 81
Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates
Chuprakov, S., Ogunkoya, A. O., Barfield, R. M., Bauzon, M., Hickle, C., Kim, Y. C., Yeo, D., Zhang, F., Rabuka, D., & Drake, P. M. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00029 · Cited by 80
Recent Advances in Drug–Antibody Ratio Determination of Antibody–Drug Conjugates
Matsuda, Y., & Mendelsohn, B. A. (2021) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00258 · Cited by 80
Ott, P. A., Pavlick, A. C., Johnson, D. B., Hart, L. L., Infante, J. R., Luke, J. J., Lutzky, J., Rothschild, N. E., S̄pitler, L. E., Cowey, C. L., et al. (2019) · Cancer · doi:10.1002/cncr.31892 · Cited by 79
Sievers, E. L. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.5.893 · Cited by 78
Milowsky, M. I., Galsky, M. D., Morris, M. J., Crona, D. J., George, D. J., Dreicer, R., Tse, K., Petruck, J., Webb, I. J., Bander, N. H., et al. (2016) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.07.005 · Cited by 78 · cited 3×
“Ocular Toxicity Ocular toxicity is one of the key off-target dose-limiting toxicities of ADCs containing the SPDB-DM4 linker-payload, such as cantuzumab ravtansine [165], mirvetuximab soravtansine [166], and coltuximab ravtansine [167], or the mc-MMAF linker-payload, such as belantamab mafodotin [119], AGS-16C3F [168]…”
InfluentialKovtun, Y., Noordhuis, P., Whiteman, K. R., Watkins, K., Jones, G. E., Harvey, L., Lai, K. C., Portwood, S., Adams, S., Sloss, C. M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1077 · Cited by 77
Bordeau, B. M., Yang, Y., & Balthasar, J. P. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3822 · Cited by 75
Self-citationZhao, H., Gulesserian, S., Ganesan, S. K., Ou, J., Morrison, K., Zeng, Z., Robles, V., Snyder, J., Do, L., Aviña, H., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0710 · Cited by 73
Matsuda, Y., & Mendelsohn, B. A. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1846714 · Cited by 73
Pillow, T. H., Schutten, M., Yu, S.-F., Ohri, R., Sadowsky, J., Poon, K. A., Solis, W., Zhong, F., Del Rosario, G., Go, M. A. T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0641 · Cited by 72
Johnson, M., El-Khoueiry, A., Hafez, N., Lakhani, N., Mamdani, H., Rodon, J., Sanborn, R. E., Garcia-Corbacho, J., Boni, V., Stroh, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0194 · Cited by 72
Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies
Liu, S., Verma, A., Kettenberger, H., Richter, W. F., & Shah, D. K. (2021) · mAbs · doi:10.1080/19420862.2021.1993769 · Cited by 72
Yan, H., Endo, Y., Shen, Y., Rotstein, D. S., Dokmanovic, M., Mohan, N., Mukhopadhyay, P., Gao, B., Pacher, P., & Wu, W. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0580 · Cited by 71
Guffroy, M., Falahatpisheh, H., Biddle, K., Kreeger, J., Obert, L., Walters, K., Goldstein, R., Boucher, G., Coskran, T., Reagan, W., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0939 · Cited by 69
Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Redman, B. G., Sangha, R. S., Ernst, D. S., Pili, R., Kim, S. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0481 · Cited by 67
An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia
Zheng, B., Yu, S.-F., del Rosario, G., Leong, S. R., Lee, G. Y., Vij, R., Chiu, C., Liang, W.-C., Wu, Y., Chalouni, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0333 · Cited by 66
Kogelberg, H., Tolner, B., Sharma, S. K., Lowdell, M. W., Qureshi, U., Robson, M., Hillyer, T., Pedley, R. B., Vervecken, W., Contreras, R., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl053 · Cited by 64
Shi, J., Guo, W., Jin, Y., Zhang, H., Pang, C., Li, J., Line, P., & Zhang, S. (2019) · Cancer Medicine · doi:10.1002/cam4.2006 · Cited by 62
Fenn, K. M., & Kalinsky, K. M. (2019) · Drugs of today · doi:10.1358/dot.2019.55.9.3039669 · Cited by 62
Miller, M. L., Shizuka, M., Wilhelm, A., Salomon, P., Reid, E. E., Lanieri, L., Sikka, S., Maloney, E. K., Harvey, L., Qiu, Q., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0940 · Cited by 56
Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
Giovannini, M., Gregorc, V., Belli, C., Roca, E., Lazzari, C., Viganò, M. G., Serafico, A., & Villa, E. (2009) · Journal of Oncology · doi:10.1155/2009/849051 · Cited by 54
Ha, S. Y. Y., Anami, Y., Yamazaki, C. M., Xiong, W., Haase, C. M., Olson, S. D., Lee, J., Ueno, N. T., Zhang, N., An, Z., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0362 · Cited by 54
Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia
Godwin, C. D., McDonald, G. B., & Walter, R. B. (2017) · Blood · doi:10.1182/blood-2017-01-762419 · Cited by 53
Tissue-specific expression of IgG receptors by human macrophages ex vivo
Bruggeman, C. W., Houtzager, J., Dierdorp, B., Kers, J., Pals, S. T., Lutter, R., van Gulik, T., den Haan, J. M. M., van den Berg, T. K., van Bruggen, R., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0223264 · Cited by 52
Terui, Y., Rai, S., Izutsu, K., Yamaguchi, M., Takizawa, J., Kuroda, J., Ishikawa, T., Kato, K., Suehiro, Y., Fukuhara, N., et al. (2021) · Cancer Science · doi:10.1111/cas.14937 · Cited by 52
Berger, M., Norvell, T. M., Tosi, M. F., Emancipator, S. N., Konstan, M. W., & Schreiber, J. R. (1994) · Pediatric Research · doi:10.1203/00006450-199401000-00015 · Cited by 50
A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists
Mecklenburg, L. (2018) · Toxicologic Pathology · doi:10.1177/0192623318803059 · Cited by 49
Innovations for Next-Generation Antibody-Drug Conjugates
(2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-78154-9 · Cited by 48
Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches
Hussain, A. F., Grimm, A., Sheng, W., Zhang, C., Al-Rawe, M., Bräutigam, K., Mraheil, M. A., Zeppernick, F. A., & Meinhold-Heerlein, I. M. (2021) · Pharmaceuticals · doi:10.3390/ph14040343 · Cited by 46
Evidence for enhanced tissue factor expression in age-related macular degeneration
Cho, Y., Cao, X., Shen, D., Tuo, J., Parver, L. M., Rickles, F. R., & Chan, C. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.184 · Cited by 45
Another look at the life of a neutrophil
Bekkering, S. (2013) · World Journal of Hematology · doi:10.5315/wjh.v2.i2.44 · Cited by 45
Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE
Jiang, J., Li, S., Shan, X., Wang, L., Ma, J., Huang, M., Dong, L., & Chen, F. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2019.12.027 · Cited by 45
In Vivo Biotransformations of Antibody–Drug Conjugates
Tumey, L. N., Rago, B., & Han, X. (2015) · Bioanalysis · doi:10.4155/bio.15.84 · Cited by 44
Gemtuzumab Ozogamicin: A Review of its Use in Acute Myeloid Leukaemia
Fenton, C., & Perry, C. M. (2005) · Drugs · doi:10.2165/00003495-200565160-00014 · Cited by 44
Tissue factor expression in human pterygium.
Andõ, R., Kase, S., Ōhashi, T., Dong, Z., Fukuhara, J., Kanda, A., Murata, M., Noda, K., Kitaichi, N., & Ishida, S. (2011) · Institutional Repositories DataBase (IRDB) · Cited by 41
Endo, Y., Mohan, N., Dokmanovic, M., & Wu, W. J. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab005 · Cited by 39
Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Bordeau, B. M., Nguyen, T. D., Polli, J. R., Chen, P., & Balthasar, J. P. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0440 · Cited by 38
Self-citationSelf-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Edupuganti, V. V. S. R., Tyndall, J. D. A., & Gamble, A. B. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210509001139 · Cited by 36 · cited 1×
“Upon cleavage by lysosomal enzymes after ADC internalization into the target cells, the PABC spacer in the vc-PAB-MMAE linker/payload goes through a cascade of disassembly reactions and facilitates the release of untethered MMAE intracellularly [197].”
Balthasar, J. P., & Fung, H. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js960135w · Cited by 35
Self-citationL’Italien, L., Orozco, O. E., Abrams, T. J., Cantagallo, L., Connor, A. V., Desai, J., Ebersbach, H., Gelderblom, H. A. J., Hoffmaster, K. A., Lees, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3786 · Cited by 34
Endo, Y., Takeda, K., Mohan, N., Shen, Y., Jiang, J., Rotstein, D. S., & Wu, W. J. (2018) · Oncotarget · doi:10.18632/oncotarget.26461 · Cited by 34
Hartimath, S. V., Alizadeh, E., Solomon, V. R., Chekol, R., Bernhard, W., Hill, W., Parada, Á. C., Barreto, K., Geyer, C. R., & Fonge, H. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220095 · Cited by 34
Moilanen, T., Jokimäki, A., Tenhunen, O., & Koivunen, J. P. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2682-9 · Cited by 32
Gong, J., Shen, L., Wang, W., & Fang, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e16059 · Cited by 32
Balthasar, J. P., & Fung, H. L. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39006-3 · Cited by 30
Self-citationPreclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody–drug conjugates
Sapra, P., Betts, A. M., & Boni, J. P. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.827405 · Cited by 30
Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates
Tada, M., Aoyama, M., & Ishii-Watabe, A. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.046 · Cited by 30
Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG
Shao, S., Tsai, M., Lu, J., Yu, T., Jin, J., Xiao, D., Jiang, H., Han, M., Wang, M., & Wang, J. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.03.005 · Cited by 29
Research works printed but not linked: 5
- GlaxoSmithKline (2023, January 17). GSK Provides an Update on Blenrep (Belantamab Mafodotin-Blmf) US Marketing Authorisation. Available online: https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/.
- Actor, J.K. (2012). Elsevier’s Integrated Review Immunology and Microbiology, W.B. Saunders. [2nd ed.].
- Herrera, 2017, A Phase I Study of the Anti-CD79b THIOMABTM-Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (B-NHL), Blood, 130, 4129
- Damelin, M. (2018). Innovations for Next-Generation Antibody-Drug Conjugates, Springer International Publishing. · DOI
- Damelin, M. (2018). Innovations for Next-Generation Antibody-Drug Conjugates, Springer International Publishing. · DOI
Cited by
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Riccardi, F., Dal Bo, M., Macor, P., & Toffoli, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274088 · Cited by 188
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
Chang, H. L., Schwettmann, B., McArthur, H. L., & Chan, I. S. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172156 · Cited by 136
Metadata
- Authors
- Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P.
- Affiliations
- University at Buffalo, State University of New York (US)
- Corresponding author
- Balthasar, Joseph P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-01-24
- Volume
- 15
- Issue
- 3
- Pages
- 713
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9913659
- OpenAlex
- W4317932204
- Cited by
- 441
- References
- 227
- Citations by year
- 2026: 150 · 2025: 172 · 2024: 99 · 2023: 20
- FWCI
- 18.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA246785, CA256928)
- University at Buffalo Center for Protein Therapeutics (CA246785, CA256928)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- antibody-drug conjugates, off-target toxicity, dose-limiting toxicity, treatment-related adverse events, toxicity mechanisms, tolerability, cytotoxic payloads, monoclonal antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.